BURLINGTON, Mass.– RedShift BioAnalytics (RedShiftBio), a company providing next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, announced the opening of their scientific services lab, StructIR Lab. Known for its Microfluidic Modulation Spectroscopy (MMS) technology, RedShiftBio’s StructIR Lab will provide institutions with the ability to access the ground-breaking technology for sample testing and proof-of-concept experiments. To celebrate the grand opening, the company is also announcing a StructIR Lab Grant program which will fund two research projects conducted at the lab.
The StructIR Lab houses several of the company’s flagship AQS3pro instruments and is staffed by a dedicated scientific team of MMS experts. Customers can either come to the lab and work side-by-side with the staff to gain hands-on experience or can choose to send samples for remote processing.
MMS overcomes many of the limitations of traditional spectroscopy-based technologies with ultrasensitive, highly reproducible, automated structural measurements of proteins and other biomolecules. It can be used for a wide range of applications from formulation development of mAb-based biotherapeutics to robust measurements of ADCs, AAVs, and mRNA.
Key features of the AQS3pro instrument include:
- Ability to measure wide range of native sample concentrations from <0.1 mg/ml to >200 mg/ml
- Fully automated sample-handling, with both 24 and 96 well plate formats
- Real-time background subtraction eliminates need to dialyse samples
- Detection of <2% change in secondary structure even at low concentrations
- Advanced onboard data analytics enabling rapid and robust data interpretation and reporting
“We are excited to celebrate the opening of our StructIR Lab with the launch of our grant program,” said Julien Bradley, CEO of RedShiftBio. “The grant program will expand access to our novel MMS technology to groups who are researching and developing pivotal biotherapeutics and vaccines. Our AQS3pro has seen wide adoption by the majority of the world’s leading biopharmaceutical companies, reducing development time, improving product quality, and de-risking development.” For more information on the StructIR Lab click here.
The 2021 StructIR Lab Grant program will provide two winners access to the AQS3pro and the lab’s staff for sample testing and analysis. The program is open to applicants in North America and Europe starting October 6. Applicants will need to complete and submit a grant application, available through the RedShiftBio website, by November 15 to be considered for this grant.
